SAN DIEGO, CA—via eTeligis—La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla"), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that the Company will present at the 16th Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria in New York City on February 10-11, 2014. George F. Tidmarsh, MD, PhD, President and Chief Executive Officer of La Jolla will present on La Jolla's recent progress at 4:30pm Eastern Time on Monday, February 10, in the Conrad Room. The presentation will also be available via webcast on the Company's website athttp://www.ljpc.com.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-501, the Company's second product candidate, is a natural peptide for the treatment of hepatorenal syndrome. For more information on the Company please visit http://www.ljpc.com.
Company Contact
George F. Tidmarsh, M.D., Ph.D.
President & Chief Executive Officer
La Jolla Pharmaceutical Company
Phone: (858) 207-4264
Email: GTidmarsh@ljpc.com
and
Chester S. Zygmont, III
Director of Finance
La Jolla Pharmaceutical Company
Phone: (858) 207-4262
Email: czygmont@ljpc.com
SOURCE: La Jolla Pharmaceutical Company
Associated Documentation:
Link to submission on http://www.eteligis.com
LPJC_2-5-14_ETL_KMG.docx
To unsubscribe from any future mailings, please visit: http://www.eteligis.com/MassMailUnsubscribe.aspx
Copyright eTeligis Inc. 2014. All rights reserved.
0 comments:
Post a Comment